Evaluating the Effect of Cabergoline on Glycaemic Control of Patients with Type 2 Diabetes Mellitus: A Randomised Controlled Trial
Introduction: Although bromocriptine has been approved as an antidiabetic agent, few studies have reported the beneficial effects of other anti-hyperglycemic long acting dopamine agonist agents. In this regard, Cabergoline has fewer side-effects than that of Bromocriptine which can be administered a...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2020-02-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://www.jcdr.net/articles/PDF/13481/43034_CE[Ra1]_F(SL)_PF1(AJ_KM)_GC(Su_KM)_PN(SL).pdf |
| _version_ | 1818329240038277120 |
|---|---|
| author | Akbar AliAsgarzadeh Sanaz Karimiavval Jalil Houshyar Morteza Gojazadeh Alireza Hadi |
| author_facet | Akbar AliAsgarzadeh Sanaz Karimiavval Jalil Houshyar Morteza Gojazadeh Alireza Hadi |
| author_sort | Akbar AliAsgarzadeh |
| collection | DOAJ |
| description | Introduction: Although bromocriptine has been approved as an antidiabetic agent, few studies have reported the beneficial effects of other anti-hyperglycemic long acting dopamine agonist agents. In this regard, Cabergoline has fewer side-effects than that of Bromocriptine which can be administered as one or two days per week with higher compliance rates in patients. Aim: To determine the effect of Cabergoline on glycaemic control in patients with Type 2 Diabetes Mellitus (DM). Materials and Methods: In this double-blind clinical trial, initial laboratory parameters including Fasting Plasma Glucose (FBS), 2 Hours Postprandial Plasma Glucose (2HPPG), HbA1c, Total Cholesterol (T-Chol), Triglycerides (TG), and High Density Lipoproteins (HDL) were assessed. The subjects were randomly assigned into two case and control groups. The intervention group received 0.25 mg Cabergoline tablets weekly for the first 2 weeks and 0.5 mg per week for the next 12 weeks. Control group also received placebo tablets. All clinical and laboratory assessments were repeated 3 months after initial visit. Paired t-test, independent t-test and chi-square were used for the comparison of quantitative and qualitative variables, respectively. Covariance analysis was also used to adjust for confounding variables. p<0.05 was considered as statistically significant. Results: HbA1c (p=0.01) and TG (0.04) levels were significantly decreased after intervention in the case group compared to the controls. Conclusion: Cabergoline, over a 3 months period, exhibits beneficial effects on HbA1C and TG levels and may possibly be useful as a long-term anti-diabetic drug in patients with type 2 DM. |
| first_indexed | 2024-12-13T12:44:54Z |
| format | Article |
| id | doaj.art-3ba8e6db96094d7eb600fb67bf05d66c |
| institution | Directory Open Access Journal |
| issn | 2249-782X 0973-709X |
| language | English |
| last_indexed | 2024-12-13T12:44:54Z |
| publishDate | 2020-02-01 |
| publisher | JCDR Research and Publications Private Limited |
| record_format | Article |
| series | Journal of Clinical and Diagnostic Research |
| spelling | doaj.art-3ba8e6db96094d7eb600fb67bf05d66c2022-12-21T23:45:30ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2020-02-01142OC01OC0410.7860/JCDR/2020/43034.13481Evaluating the Effect of Cabergoline on Glycaemic Control of Patients with Type 2 Diabetes Mellitus: A Randomised Controlled TrialAkbar AliAsgarzadeh0Sanaz Karimiavval1Jalil Houshyar2Morteza Gojazadeh3Alireza Hadi4Department of Internal Medicine, Endocrine Research Centre, Tabriz University of Medical Sciences, Tabriz, East Azarbayjan, Iran.Department of Internal Medicine, Endocrine Research Centre, Tabriz University of Medical Sciences, Tabriz, East Azarbayjan, Iran.Department of Internal Medicine, Endocrine Research Centre, Tabriz University of Medical Sciences, Tabriz, East Azarbayjan, Iran.Department of Internal Medicine, Faculty of Medicine, Research Centre for Evidence Based Medicine, Tabriz University of Medical Sciences, East Azarbayjan, Iran.Department of Internal Medicine, Endocrine Research Centre, Tabriz University of Medical Sciences, Tabriz, East Azarbayjan, Iran.Introduction: Although bromocriptine has been approved as an antidiabetic agent, few studies have reported the beneficial effects of other anti-hyperglycemic long acting dopamine agonist agents. In this regard, Cabergoline has fewer side-effects than that of Bromocriptine which can be administered as one or two days per week with higher compliance rates in patients. Aim: To determine the effect of Cabergoline on glycaemic control in patients with Type 2 Diabetes Mellitus (DM). Materials and Methods: In this double-blind clinical trial, initial laboratory parameters including Fasting Plasma Glucose (FBS), 2 Hours Postprandial Plasma Glucose (2HPPG), HbA1c, Total Cholesterol (T-Chol), Triglycerides (TG), and High Density Lipoproteins (HDL) were assessed. The subjects were randomly assigned into two case and control groups. The intervention group received 0.25 mg Cabergoline tablets weekly for the first 2 weeks and 0.5 mg per week for the next 12 weeks. Control group also received placebo tablets. All clinical and laboratory assessments were repeated 3 months after initial visit. Paired t-test, independent t-test and chi-square were used for the comparison of quantitative and qualitative variables, respectively. Covariance analysis was also used to adjust for confounding variables. p<0.05 was considered as statistically significant. Results: HbA1c (p=0.01) and TG (0.04) levels were significantly decreased after intervention in the case group compared to the controls. Conclusion: Cabergoline, over a 3 months period, exhibits beneficial effects on HbA1C and TG levels and may possibly be useful as a long-term anti-diabetic drug in patients with type 2 DM.https://www.jcdr.net/articles/PDF/13481/43034_CE[Ra1]_F(SL)_PF1(AJ_KM)_GC(Su_KM)_PN(SL).pdffasting blood glucosehba1clong acting dopamine agonist |
| spellingShingle | Akbar AliAsgarzadeh Sanaz Karimiavval Jalil Houshyar Morteza Gojazadeh Alireza Hadi Evaluating the Effect of Cabergoline on Glycaemic Control of Patients with Type 2 Diabetes Mellitus: A Randomised Controlled Trial Journal of Clinical and Diagnostic Research fasting blood glucose hba1c long acting dopamine agonist |
| title | Evaluating the Effect of Cabergoline on Glycaemic Control of Patients with Type 2 Diabetes Mellitus: A Randomised Controlled Trial |
| title_full | Evaluating the Effect of Cabergoline on Glycaemic Control of Patients with Type 2 Diabetes Mellitus: A Randomised Controlled Trial |
| title_fullStr | Evaluating the Effect of Cabergoline on Glycaemic Control of Patients with Type 2 Diabetes Mellitus: A Randomised Controlled Trial |
| title_full_unstemmed | Evaluating the Effect of Cabergoline on Glycaemic Control of Patients with Type 2 Diabetes Mellitus: A Randomised Controlled Trial |
| title_short | Evaluating the Effect of Cabergoline on Glycaemic Control of Patients with Type 2 Diabetes Mellitus: A Randomised Controlled Trial |
| title_sort | evaluating the effect of cabergoline on glycaemic control of patients with type 2 diabetes mellitus a randomised controlled trial |
| topic | fasting blood glucose hba1c long acting dopamine agonist |
| url | https://www.jcdr.net/articles/PDF/13481/43034_CE[Ra1]_F(SL)_PF1(AJ_KM)_GC(Su_KM)_PN(SL).pdf |
| work_keys_str_mv | AT akbaraliasgarzadeh evaluatingtheeffectofcabergolineonglycaemiccontrolofpatientswithtype2diabetesmellitusarandomisedcontrolledtrial AT sanazkarimiavval evaluatingtheeffectofcabergolineonglycaemiccontrolofpatientswithtype2diabetesmellitusarandomisedcontrolledtrial AT jalilhoushyar evaluatingtheeffectofcabergolineonglycaemiccontrolofpatientswithtype2diabetesmellitusarandomisedcontrolledtrial AT mortezagojazadeh evaluatingtheeffectofcabergolineonglycaemiccontrolofpatientswithtype2diabetesmellitusarandomisedcontrolledtrial AT alirezahadi evaluatingtheeffectofcabergolineonglycaemiccontrolofpatientswithtype2diabetesmellitusarandomisedcontrolledtrial |